That was the president yesterday in a press conference with Dr. . Oz suggesting that out-of- pocket prices for Ozepic could soon be made lower. Shares of Eli Liy and Nova you can see under some pressure this morning as a result of those comments.Joining us now to break down the moveo healthc care strategist Jared Holes. So Jared, what do you make of those comments. What do they mean for either one of these key drug makers.>> Hey David, how are you. Um I'm not that surprised. I mean, this this seems like, yo ...

Core Insights - American Express shares increased after the company reported strong quarterly results that exceeded analysts' expectations and raised its outlook due to increased customer usage of its high-end credit cards [2][6]. Group 1: Market Performance - Major U.S. equity indexes rose at midday on Friday, with regional bank stocks recovering from previous losses following a series of corporate earnings reports [1][6]. - Kenvue was the top performer in the S&P 500 as investors capitalized on a dip in its stock price after a lawsuit in the U.K. claimed its baby powder caused cancer [2]. - Truist Financial also reported better-than-expected results, driven by higher wealth management fees and interest income, leading to a rise in its share price [3]. Group 2: Sector Movements - Shares of Newmont and other gold miners declined as the price of gold, which had been reaching record highs, experienced a pullback [3]. - U.S.-listed shares of Novo Nordisk and Eli Lilly fell after comments from President Trump regarding potential price reductions for popular weight-loss drugs [3][6]. Group 3: Economic Indicators - The yield on the 10-year Treasury note and oil futures saw slight increases, while the U.S. dollar strengthened against the euro and pound but weakened against the yen [4].

Core Insights - Novo Nordisk (NVO) shares declined approximately 4% in pre-market trading following U.S. President Donald Trump's indication of potential significant price reductions for the company's GLP-1 RA drugs, Ozempic and Wegovy, which have been crucial for the company's growth [1][7] - Trump suggested that the prices of these drugs could decrease to around $150 out-of-pocket for Americans, although formal negotiations have not yet commenced [2][3] - The reduction in drug prices could enhance access for diabetes and obesity patients but raises concerns about the implications for drug development economics and future medical innovations [4][11] Company Performance - Year-to-date, NVO stock has dropped 34.7%, contrasting with a 5.5% growth in the industry [6] - The company has faced challenges with slowing uptake of Wegovy and increased competition from Eli Lilly, prompting a restructuring plan aimed at saving around DKK 8 billion by 2026 through workforce reductions [10][11] Competitive Landscape - Eli Lilly, a key competitor, has seen rapid demand for its tirzepatide-based drugs, Mounjaro and Zepbound, which generated combined sales of $14.7 billion in the first half of 2025, accounting for 52% of Lilly's total revenues [12] - Following Trump's comments, Eli Lilly's shares also fell about 4% in pre-market trading, indicating investor concerns regarding similar pricing pressures for its GLP-1 therapies [13] Market Dynamics - The potential price cuts for GLP-1 drugs could deter pharmaceutical companies from investing in research and development, impacting future innovations in the industry [11]

Core Viewpoint - Novo Nordisk shares have significantly declined due to increased competition in the weight-loss drug market and recent comments from President Trump regarding price reductions for these medications [1][4]. Group 1: Market Impact - Shares of Novo Nordisk fell over 4% in early trading, while Eli Lilly's shares dropped by 3% following President Trump's announcement about potential price cuts for weight-loss drugs [2][3]. - President Trump indicated that the price of Novo Nordisk's Ozempic could decrease from $1,300 to $150 per month, which has raised concerns among investors [2][4]. Group 2: Competitive Landscape - Novo Nordisk has lost more than a third of its market value this year, attributed to intensifying competition in the weight-loss drug sector [1][4]. - Eli Lilly's shares have shown a slight increase of about 3% during the same period, indicating a different market response compared to Novo Nordisk [4]. Group 3: Regulatory Environment - The Centers for Medicare & Medicaid Services, led by Dr. Mehmet Oz, has not yet completed negotiations with pharmaceutical companies regarding drug pricing, which adds uncertainty to the market [2][5]. - A spokesperson from Novo Nordisk stated that the company is actively engaging with the Trump administration to find solutions for medication accessibility [4].

Core Insights - President Trump's proposal to reduce the price of Novo Nordisk's Ozempic from approximately $1,300 to $150 could significantly impact the GLP-1 market and healthcare valuations across major pharmaceutical companies [1][2][3] Novo Nordisk - The discussions regarding price cuts have positioned Novo Nordisk as a focal point in the administration's cost-reduction efforts, with the company confirming talks under the Most Favored Nation executive order [2] - The semaglutide franchise, which includes Ozempic and Wegovy, is projected to account for over 50% of Novo Nordisk's revenue in 2024, indicating that potential price caps could severely affect profit margins [3] Eli Lilly - Eli Lilly, which has GLP-1 drugs like Mounjaro and Zepbound, may face pressure to adjust pricing in response to Novo Nordisk's potential price cuts, risking public backlash if it does not comply [4] - A 20% reduction in average selling prices could lead to a loss of several billion dollars in projected operating income for Eli Lilly in 2025 [5] Other Pharmaceutical Companies - Trump's pricing strategy may provide opportunities for other pharmaceutical companies like Pfizer and Amgen, which could benefit from a shift in investor focus towards lower-cost alternatives [6] - Pfizer, which has struggled with its oral GLP-1 candidate, might regain traction if pricing caps create a more competitive environment [6] - Amgen, developing a dual-agonist version of GLP-1, could also see increased interest as investors look for next-generation solutions [6] Market Dynamics - The proposed price cuts could lead to a significant reshuffling in the weight-loss pharmaceutical market, with Novo Nordisk and Eli Lilly potentially losing their competitive edge while Pfizer and Amgen could emerge as new leaders [7]

Core Insights - Concerns over lending standards in U.S. markets have led to a sell-off among major private markets firms in Europe, with significant declines in stock prices for firms like ICG, CVC Capital Partners, Partners Group, and EQT [1][2] Group 1: Market Reactions - ICG's stock fell approximately 6%, CVC Capital Partners lost about 5.4%, Partners Group declined by 4%, and EQT was down 4% [1] - The sell-off in Europe follows a broader decline among U.S. regional banks due to fears of risky lending practices affecting the banking sector [2] Group 2: Asset Management and Exposure - ICG manages over $30 billion in private debt assets, constituting about 25% of its total assets under management as of late June [2] - Partners Group oversees $38 billion in private credit, while CVC's private credit business focuses on direct lending opportunities and manages approximately €17 billion ($19.9 billion) [2] Group 3: Credit Quality Concerns - Recent events, including the bankruptcy of subprime auto lender Tricolor and the collapse of First Brands, have heightened scrutiny on credit quality and lending practices [3][4] - First Brands' issues were linked to complex borrowing arrangements, raising alarms about increased leverage and lax credit standards across the industry [4] Group 4: Industry Warnings - J.P. Morgan CEO Jamie Dimon indicated that there may be hidden stress within the credit system, suggesting that the current situation could reveal more underlying issues [5]

Core Viewpoint - Eli Lilly (LLY.US) experienced a significant stock decline of over 4%, marking the largest intraday drop since August 7, with shares trading at $797.78. This was triggered by President Trump's comments regarding the potential reduction of the price of the diabetes drug Ozempic to as low as $150 per month, causing market volatility. However, CMS Administrator Mehmet Oz clarified that price negotiations are still ongoing and no agreement has been reached [1]. Company Summary - Eli Lilly's stock price fell over 4%, reaching $797.78, the largest drop since early August [1]. - The potential price reduction of Ozempic to $150 per month was highlighted by President Trump, which contributed to the market reaction [1]. - CMS Administrator Mehmet Oz stated that price negotiations for Ozempic are still in progress and no final agreement has been established [1].

Core Viewpoint - Trump announced that the list price of Ozempic, referred to as "the fat loss drug," will be "much lower" [1] Group 1 - The statement regarding Ozempic's price reduction indicates potential changes in the pharmaceutical market dynamics [1]

Market Overview - Stock index futures are down, with S&P 500 futures declining by 1%, Nasdaq 100 futures by 1.2%, and Dow futures by 0.75% due to concerns regarding the health of regional banks [3] - Major averages on Wall Street closed lower on the previous day [4] Banking Sector - Bank stocks are predominantly losers in early trading, reflecting negative sentiment in the market [5] - Zions Bancorp reported a $50 million charge-off, and Western Alliance alleged fraud on loans, raising concerns reminiscent of the regional bank stress following the SVB collapse in March 2023 [6] Pharmaceutical Sector - Novo Nordisk's stock fell by 4% after President Trump announced a potential reduction in the price of Ozempic, a leading weight-loss medication, which currently has a list price of approximately $1,000 per month [7][10] - Eli Lilly's shares dropped by 5% in premarket trading, as it also produces similar treatments [10] Automotive Sector - Ford is recalling nearly 625,000 vehicles in the U.S. due to seatbelt and rear-view camera display issues [11] - The recall includes 332,778 Ford Mustang cars for seatbelt concerns and 291,901 F-Series trucks for faulty camera displays, with dealers set to address these issues at no charge [12] Technology Sector - Micron Technology's shares decreased by 4% following reports of halting sales of server chips to data centers in China due to a business slump linked to a ban on its products in critical infrastructure [14]

每经AI快讯，10月17日，礼来盘前跌超4%，诺和诺德跌近4%。 ...